Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis

@inproceedings{Zhang2015EfficiencyOC,
  title={Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis},
  author={Tengfei Zhang and Ling Cao and Jing Xie and Ni Shi and Zhen Zhang and Zhenzhen Luo and Dongli Yue and Zimeng Zhang and Liping Wang and Weidong Han and Zhongwei Xu and Hu Chen and Yi Zhang},
  booktitle={Oncotarget},
  year={2015}
}
Chimeric antigen receptor (CAR) modified T cells targeted CD19 showed promising clinical outcomes in treatment of B cell malignances such as chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) and other indolent lymphomas. However, the clinical benefit varies tremendously among different trials. This meta-analysis investigated the efficacy (response rates and survival time) of CD19-CAR T cells in refractory B cell malignances in Phase I clinical trials. We searched… CONTINUE READING
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 40 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES

Similar Papers

Loading similar papers…